TEL AVIV, Israel--(BUSINESS WIRE)--Jun. 16, 2015--
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, announced today that its
Chief Financial and Operating Officer, Philip Serlin, will be presenting
at the JMP Securities annual life sciences equity research conference
being held at the St. Regis Hotel in New York.
The BioLineRx presentation is scheduled to start at 11:00 a.m. EDT on
Tuesday, June 23, 2015. A live audio webcast of the presentation will be
available online at the BioLineRx
Events Web Page. An archive of the event will also be available for
those unable to listen live.
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a
pivotal CE-Mark registration trial scheduled for completion in mid-2015;
BL-8040, a cancer therapy platform, which is in the midst of a Phase 2
study for acute myeloid leukemia (AML), and has successfully completed a
Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease,
which has successfully completed a Phase 1/2 study.
In December 2014, BioLineRx entered into a strategic collaboration
with Novartis for the co-development of selected Israeli-sourced novel
drug candidates. The companies intend to co-develop a number of
pre-clinical and early clinical therapeutic projects through clinical
proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150616005743/en/
Source: BioLineRx Ltd.
Strategic Advisors, Inc.
Joshua Drumm, Ph.D., +1-212-375-2664
Tsipi Haitovsky, +972-3-6240871